03/09/23 6:59 AMNasdaq : GRNA GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D DayProgressing human health pipeline conferring mRNA platform advantages for infectious disease and personalized oncology medicines; pursuing capital efficient strategy targeting unmet medical needs, in both the developed and lower- and middle-income countries (LMICs), pairing focused R&D spendRHEA-AIvery positive
03/07/23 6:59 AMNasdaq : GRNA GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D DayGreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, will today outline its pipeline strategy and R&DRHEA-AIpositive
03/01/23 6:24 AMNasdaq : GRNA conferencesGreenLight Biosciences to Host R&D Day Series on Plant and Human Health Development StrategyGreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today announced it will host a two-part R&D Day SeriesRHEA-AIneutral
02/01/23 7:20 AMNasdaq : GRNA clinical trialcovid-19GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidateThe Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase I/II clinical trial is the first step in GreenLight’s integrated strategy of bringing a universal Covid-19 mRNA vaccine to market globally. ByRHEA-AIneutral
01/09/23 7:20 AMNasdaq : GRNA GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer VaccinesThe effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine design Epivax Therapeutics, Inc. will contribute a proprietary set of immunoinformatics tools for rapidly identifying and differentiating highlyRHEA-AIvery positive
11/09/22 5:07 PMNasdaq : GRNA earningsGreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company ProgressWorking toward clinical trial initiation for COVID vaccine candidate in 2023 Shingles vaccine candidate selection planned for 2023 in partnership with Serum Institute of India Calantha™, Colorado potato beetle solution, commercial launch planned for 2023, subject to regulatory approval HoneybeeRHEA-AIpositive
11/07/22 11:25 AMNasdaq : GRNA conferencesGreenLight Biosciences to Participate in Upcoming Investor Conferences in NovemberGreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world’s toughest problems in human health and agriculture, today announced that Dr. Andrey Zarur, CEO, and Susan Keefe,RHEA-AIneutral
10/12/22 6:54 AMNasdaq : GRNA GreenLight Biosciences announces realignment to focus on near-term value driversGreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today announcedRHEA-AIvery positive
10/05/22 9:35 AMNasdaq : GRNA partnershipGreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNAGreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armyworm Fall armyworm is one of the most destructive insect pests on the planet, causing more than US$2 billion in annual crop loss worldwide The Australian government has been searching forRHEA-AIvery positive
08/15/22 7:30 AMNasdaq : GRNA earningsGreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company ProgressGreenLight raised $108.4 million in private placement led by S2G Ventures with strong participation from existing and new investors with cash expected to fund critical programs through the first half of 2023. GreenLight and Samsung Biologics completed their first commercial-scale engineering runRHEA-AIpositive